A partnership to bring early detection of visual diseases to people living with diabetes.
Ainnova Tech joined forces with Roche and Salud 360 to advance the early detection of visual diseases in people living with diabetes. The collaboration brings together Ainnova's AI-powered retinal screening with the reach and expertise of its partners.
Early detection of diabetic retinopathy and other retinal conditions is critical to preventing avoidable blindness — and partnerships like this one help make screening more accessible across the region.
Roche is one of the world's largest healthcare companies, a global leader in pharmaceuticals and in-vitro diagnostics, with a long-standing focus on diabetes care.
Salud 360 is a Costa Rican health-tech founded in 2020 by a group of physicians, clinics and laboratories. The pilot set out to screen at least 300 patients with uncontrolled diabetes in Costa Rica, referring at-risk patients immediately to ophthalmology specialists.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: Reported by Delfino.cr ↗
Contact: Ainnova Tech — info@ainnovatech.com